Literature DB >> 35915199

Micro-fluidic Spray Freeze Dried Ciprofloxacin Hydrochloride-Embedded Dry Powder for Inhalation.

Yingjie Chen1, Shen Yan1, Shengyu Zhang1, Quanyi Yin2, Xiao Dong Chen1, Winston Duo Wu3.   

Abstract

Active pharmaceutical ingredient (API)-embedded dry powder for inhalation (AeDPI) is highly desirable for pulmonary delivery of high-dose drug. Herein, a series of spray freeze-dried (SFD) ciprofloxacin hydrochloride (CH)-embedded dry powders were fabricated via a self-designed micro-fluidic spray freeze tower (MFSFT) capable of tuning freezing temperature of cooling air as the refrigerant medium. The effects of total solid content (TSC), mass ratio of CH to L-leucine (Leu) as the aerosol dispersion enhancer, and the freezing temperature on particle morphology, size, density, moisture content, crystal properties, flowability, and aerodynamic performance were investigated. It was found that the Leu content and freezing temperature had considerable influence on the fine particle fraction (FPF) of the SFD microparticles. The optimal formulation (CH/Leu = 7:3, TSC = 2%w/w) prepared at - 40°C exhibited remarkable effective drug deposition (~ 33.38%), good aerodynamic performance (~ 47.69% FPF), and excellent storage stability with ultralow hygroscopicity (~ 1.93%). This work demonstrated the promising feasibility of using the MFSFT instead of conventional liquid nitrogen assisted method in the research and development of high-dose AeDPI.
© 2022. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  Active pharmaceutical ingredient-embedded dry powder for inhalation (AeDPI); Adjustable freezing temperature; High fine particle fraction; Porous and brittle microparticle; Spray freeze drying

Mesh:

Substances:

Year:  2022        PMID: 35915199     DOI: 10.1208/s12249-022-02371-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   4.026


  38 in total

Review 1.  Novel alternative methods for the delivery of drugs for the treatment of asthma.

Authors:  Hak Kim Chan; Nora Y K Chew
Journal:  Adv Drug Deliv Rev       Date:  2003-07-18       Impact factor: 15.470

Review 2.  Recent advances in aerosolised drug delivery.

Authors:  Akshay Chandel; Amit K Goyal; Goutam Ghosh; Goutam Rath
Journal:  Biomed Pharmacother       Date:  2019-02-16       Impact factor: 6.529

3.  Current and Emerging Inhaled Therapies of Repositioned Drugs.

Authors:  David Cipolla; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08       Impact factor: 15.470

4.  Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.

Authors:  Leonard J Dunn; Edward M Kerwin; Kiernan DeAngelis; Patrick Darken; Michael Gillen; Paul Dorinsky
Journal:  Pulm Pharmacol Ther       Date:  2019-12-10       Impact factor: 3.410

Review 5.  Dry powder inhalation: past, present and future.

Authors:  A H de Boer; P Hagedoorn; M Hoppentocht; F Buttini; F Grasmeijer; H W Frijlink
Journal:  Expert Opin Drug Deliv       Date:  2016-08-30       Impact factor: 6.648

6.  Will pulmonary drug delivery for systemic application ever fulfill its rich promise?

Authors:  David Cipolla
Journal:  Expert Opin Drug Deliv       Date:  2016-08-05       Impact factor: 6.648

7.  Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats.

Authors:  Eride Quarta; Veronica Chierici; Lisa Flammini; Massimiliano Tognolini; Elisabetta Barocelli; Anna Maria Cantoni; Gabriela Dujovny; Susana Ecenarro Probst; Fabio Sonvico; Gaia Colombo; Alessandra Rossi; Ruggero Bettini; Paolo Colombo; Francesca Buttini
Journal:  J Control Release       Date:  2020-04-21       Impact factor: 9.776

Review 8.  Inhaled formulations and pulmonary drug delivery systems for respiratory infections.

Authors:  Qi Tony Zhou; Sharon Shui Yee Leung; Patricia Tang; Thaigarajan Parumasivam; Zhi Hui Loh; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2014-10-24       Impact factor: 15.470

Review 9.  Levodopa Inhalation Powder: A Review in Parkinson's Disease.

Authors:  Julia Paik
Journal:  Drugs       Date:  2020-06       Impact factor: 9.546

Review 10.  Inhalation device options for the management of chronic obstructive pulmonary disease.

Authors:  Michael DePietro; Ileen Gilbert; Lauren A Millette; Michael Riebe
Journal:  Postgrad Med       Date:  2017-12-05       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.